Nevrox Overview

  • Status
  • Private
  • Latest Deal Type
  • Accelerator/​Inc
  • Investors
  • 1

Nevrox General Information


Developer of a neuroprotective small molecule drug intended for the treatment of Huntington disease (HD) and Amyotrophic Lateral Sclerosis (ALS). The company targets neurodegenerative disorders, enabling healthcare professionals to avoid characteristic misfolded proteins that aggregate and induce neuronal toxicity and death.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Accelerator/Incubator Backed
Primary Industry
Drug Discovery
Other Industries
Primary Office
  • Rehov Ilan Ramon 2
  • Nes Ziona 7403635
  • Israel
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Nevrox Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Accelerator/Incubator Completed Startup
To view Nevrox’s complete valuation and funding history, request access »

Nevrox Executive Team (2)

Name Title Board Seat Contact Info
Niva Segev Amzaleg Chief Scientific Officer
Brent Stockwell Ph.D Founder & Advisor
To view Nevrox’s complete executive team members history, request access »

Nevrox Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
FutuRx Accelerator/Incubator Minority 000 0000 000000 0
To view Nevrox’s complete investors history, request access »